Inoculation of suckling mice with coxsackievirus B, (CB4) results in the death of a majority of the animals. In this study we selected antigenic variants of CB, in the presence of neutralizing monoclonal antibodies and tested them to see whether they were attenuated. Antigenic variants selected with a single antibody showed little or no attenuation by producing a high mortality (60 to 100 %). A double variant selected with two antibodies showed considerable attenuation by causing only 25~o mortality. A triple variant selected with three antibodies was almost completely attenuated (killed only 5 % of the animals). Polypeptides from these variants were tested for their ability to interact with the monoclonal antibodies used for their selection. These studies showed that resistance of variant virus to neutralization in general was due to the inability of the antibody to bind to the virus. However, one of the antibodies could bind but not neutralize the virus, perhaps due to an alteration in the epitope. It is concluded that selection of CB, variants using more than one neutralizing monoclonal antibody can lead to attenuation of the virus.
presence of an ascites fluid without anti-CB4 activity (antibody 93). All viruses were passaged once in LLC-MKz cells. Lysates of the infected cells were clarified at 3000g for 10 min and then stored at -70 °C.
Coxsackievirus proteins were radiolabelled after infecting LLC-MK2 cells with variants Vo, V~, V z and V3 at an m.o.i, of 10; the virus was adsorbed for 1 h at 37 °C and medium (MEM) without methionine was added to the infected cells. After 2 h, the above medium supplemented with [35S]methionine (100 ~tCi/ml) was added. After 6 to 7 h of incubation, infected cells were lysedin 1 ml lysis buffer (0.2 ~ SDS, 0.5 ~ sodium deoxycholate (DOC), 0.5 ~ NP40 and 0.85 sodium chloride). The extract was centrifuged at 45000 r.p.m, for 60 min in an ultracentrifuge (Beckman L5-50). To 400 ~tl of the extract, an equal volume of spent medium from a mouse myeloma culture was added and incubated for 1 h at room temperature. To this 200 ~tl of a 10~ Protein A-bearing staphylococcus suspension was added, and after incubation for 30 min at room temperature, the mixture was centrifuged in an Eppendorf centrifuge for 5 min. The supernatant (labelled extract) was used as the source of CB4 proteins. For immunoprecipitation assays, 40 to 60 ~tl of the labelled extract (approximately 1 x 106 c.p.m.) was mixed with 20 to 30 p.1 of antibody against CB4 and the mixtures were incubated overnight at 4 °C. Protein A-Sepharose (100/al of a 50~ suspension) or staphylococcus bearing Protein A (50 ~tl of a 10~ suspension) was added to each tube, incubated for 1 h, and centrifuged in an Eppendorf centrifuge for 2 min. The pellets were washed once with 100 ~tl of Tris-HC1 (0.01 M, pH 7.4) containing 150 mM-NaC1, 0.1 ~ SDS, 0.1~ DOC, 0-1 ~ NP40, and 1 mM-PMSF and further washed twice with Tris-HCl (0.01 M, pH 7.4) containing 150 mM-NaC1 and 1 mM-PMSF. The washed pellets were then boiled in 100 pl of sample buffer (Laemmli, 1970) for 2 min and were subjected to SDS-PAGE on a 12.5 to 17.5~ gradient gel. Labelled parental CB~-infected cell extract immunoprecipitated with myeloma culture supernatant, uninfected cell extract treated with viral antibody and labelled purified CB4 were run as controls. The gel was treated with Autofluor, dried, and used to expose Kodak X-Omat AR-5 X-ray film at -70 °C for 8 to 15 days.
The putative antigenic variants were tested against the corresponding monoclonal antibodies used for their selection and were found to resist neutralization (data not shown), confirming that they were true variants. Four-day-old NIH/Swiss mice were inoculated intraperitoneally with 1 × 105 p.f.u, of either parental or variant CB4. As shown in the table, the prototype virus (CB4) and V 0 produced 100 K and 98~ mortality, respectively, and virus So grown in the presence of control antibody 93 produced mortality in 81 ~ of the animals. The single variants (selected with one antibody) caused 62 to 100 ~ mortality in suckling mice. However, when mice were infected with the V2 variant (selected with two antibodies), there was a dramatic decline in mortality to 25 ~. Inoculation of mice with the V3 variant (selected with three antibodies) resulted in a further reduction of mortality, to 5 %. These variants exhibited no apparent differences in their ability to grow in monkey kidney cell cultures (data not shown). Together, these data showed that variants selected with a single monoclonal antibody were, at best, only marginally attenuated, whereas selection of variants with more than one antibody resulted in almost complete attenuation of the virus.
The resistance to neutralization of the variant viruses could be due to either a lack of or to an alteration in an epitope. In order to test this, we immunoprecipitated variant virus-infected cell extracts with the monoclonal antibodies and subjected them to SDS-PAGE. Fig. 1 shows the immunoprecipitation of virus-infected cell extracts with the polyclonal serum 0anes 1), monoclonal antibodies 356 (lanes 2), 204 (lanes 3) and 183 (lanes 4). All antibodies precipitated some of the viral polypeptides derived from the parental virus (V0). The polyclonal antiserum and 356 also precipitated what appeared to be the precursor protein VP0. The antiserum (lanes 1) and the monoclonal antibody 356 (lanes 2) reacted similarly with all viruses. However, antibodies 204 (lanes 3) and 183 (lanes 4) reacted strongly with the parental virus (Vo) but reacted weakly with polypeptides from variants V1 and V2. As expected, polypeptides derived from variant V3 (selected with antibodies 356, 183 and 204) showed no reactivity with antibodies 183 and 204. These data showed that, although the variants V 1, V2 and V3 were resistant to neutralization by antibody 356 (data not shown), polypeptides from these viruses continued to react with this antibody. Furthermore, selection of variants with antibody 356 resulted in variants that bound poorly to antibodies 204 and 183. Further selection of variants with antibodies 183 and 204 (V3) resulted in a total loss of recognition by these antibodies.
In this study we have shown that antigenic variants of CB4 selected with a single monoclonal antibody exhibit little or no change in their ability to kill suckling mice. However, antigenic variants selected with more than one monoclonal antibody exhibited dramatic changes in their pathogenic potential. Although we used antibodies 356, 183 and 204 which have unique specificities Prabhakar et al., 1982) to select these variants, we do not know whether similar selection of variants with other antibodies would result in attenuation or some other change. Nevertheless, it is clear from these studies that variants of CB4 with different biological activities can be selected from the same parental virus. Previous reports have shown some antigenic differences among myocardiotropic and amyocardiotropic isolates of coxsackieviruses (Cao et al., 1984a, b; Gauntt et al., 1979; ). In addition, recent studies using a panel of 20 monoclonal antibodies have delineated both qualitative and quantitative differences between two isolates of CB4, one which causes high mortality in adult BALB/c mice (Edwards isolate) and the other being totally nonpathogenic (JVB isolate) (Webb et al., 1986) . These and other studies (Coulon et al., 1982; Dietzschold et al., 1983; Evans et al., 1985 ; Spriggs et al., 1983 ) support the ideas that infection with different variants of a virus can lead to different outcomes.
There were no apparent differences between V0, V1, V2 and V3 in their ability to grow in cultures in vitro and yet they showed differences in their ability to kill suckling mice. The underlying mechanism for this change in pathogenicity is not clear. In other studies, similar differences have been attributed to different immunological responses elicited by the viral variants (Yoon et al., 1980) . In our experiments this was probably not a major factor, since the mice used were immunologically immature. However, our data showed that there are some antigenic differences between the parental and the variant virus. It has been shown that serial passage of coxsackievirus B3 in rhabdomyosarcoma cells leads to changes in the receptor specificity of the virus (Reagan et al., 1984) . These studies also showed that there is more than one site on the virus that can interact with cellular receptors. Similarly, growing CB4 in the presence of monoclonal antibodies may have resulted in variants with altered receptor specificity. This may explain why there was no apparent difference in the ability of our variants to grow in cell culture although they differed in their pathogenicity for mice.
Antigenic variants selected in the presence of monoclonal antibodies commonly do not bind to the selecting antibody and are not neutralized by it. Our results support this generalization, except for antibody 356. There are several explanations for this, but the most likely is that antibody 356 recognizes a complex epitope and that interaction of this antibody with the whole complex is required for neutralization. However, if the variants express only a part of the complex, then the antibody can still bind to it without being able to neutralize the virus.
Using variants of Sindbis virus selected with one or more monoclonal antibodies, Stec et al. (1985) showed that these viruses have a 'considerable propensity for change without concurrent loss of infectivity'. However, the present study shows that changes in just a few epitopes on CB4 can lead to changes in its biological properties. The availability of these variants may allow us to establish in further detail relationships between the structure and function of coxsackieviruses. These and other studies (Fields, 1983; Prabhakar et al., 1983; suggest that variants with different tissue tropisms may be responsible for the different clinical syndromes produced by CB4.
